Teva files petition with U.S. FDA against MS drug competitors

TEL AVIV, July 3 (Reuters) - Teva Pharmaceutical Industries has filed a so-called citizen petition with the U.S. Food and Drug Administration (FDA), aiming to delay cheap generic competition to Copaxone, its top-selling treatment for multiple sclerosis (MS).
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.